抗ADAM17 (human), mAb (rec.) (blocking) (D1(A12)) (Fab Fragment) (His)抗体 | Anti-ADAM17 (human), mAb (rec.) (blocking) (D1(A12)) (Fab Fragment) (His) antibody | Adipogen
掲載日情報:2017/10/30 現在Webページ番号:205439
Adipogen社の抗ADAM17 (human), mAb (rec.) (blocking) (D1(A12)) (Fab Fragment) (His)抗体(Anti-ADAM17 (human), mAb (rec.) (blocking) (D1(A12)) (Fab Fragment) (His) antibody)です。
※本製品は研究用です。研究用以外には使用できません。
[在庫・価格 :2025年04月26日 15時15分現在]
詳細 | 商品名 |
|
文献数 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anti-ADAM17 (human), mAb (rec.) (blocking) (D1(A12)) (Fab Fragment) (His) |
|
0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
[在庫・価格 :2025年04月26日 15時15分現在]
Anti-ADAM17 (human), mAb (rec.) (blocking) (D1(A12)) (Fab Fragment) (His)
文献数: 0
- 商品コード:AG-27B-6003PF-C100
- メーカー:KOM
- 包装:100μg
- 価格:¥101,000
- 在庫:無(未発注)
- 納期:2週間程度 ※※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。
- 法規制等:
説明文 | 純度:>95% (SDS-PAGE) 別名:TNF-alpha-converting Enzyme,Disintegrin and Metalloproteinase Domain-containing Protein 17,CD156b クローン:D1(A12) Protein Accession No: P78536 |
||
---|---|---|---|
法規制等 | |||
保存条件 | -20℃ | 法規備考 | |
抗原種 | 免疫動物 | Human | |
交差性 | Human | 適用 | Blocking,Functional Analysis |
標識 | Unlabeled | 性状 | |
吸収処理 | クラス | ||
クロナリティ | Recombinant | フォーマット | |
掲載カタログ |
|
||
製品記事 | 組換えモノクローナル抗体「RecMAbs」 |
||
関連記事 | ファージディスプレイ技術による組換え抗体(AdipoGen Life Sciences社) |
追加しました。
製品説明
ADAM17 (Disintegrin and metalloproteinase domain-containing protein 17), also called TACE (Tumor necrosis factor-α-converting enzyme) is the prototype of the ADAM family of ectodomain shedding proteases (sheddase). ADAM17 is understood to be involved in the processing of TNF-α at the surface of the cell and from within the intracellular membranes of the trans-Golgi network. This process involves the cleavage and release of a soluble ectodomain from membrane-bound pro-proteins (such as pro-TNF-α) and is of known physiological importance. ADAM17 is responsible for the processing of a diverse variety of membrane-anchored cytokines, cell adhesion molecules, receptors, ligands and enzymes, including cleaving epidermal growth factor receptor (EGFR) ligands and extracellular Notch1. The proteolytic cleavage is an indispensable activation event for many of these substrates, ADAM17 has emerged as an attractive therapeutic target for the treatment of inflammatory diseases (e.g. rheumatoid arthritis) or inflammation associated cancer.
追加しました。
製品情報
Clone | D1(A12) |
---|---|
Isotype | Human Fab fragment, κ, His-tagged |
Source/Host | E. coli |
Immunogen/Antigen | Recombinant human ADAM17 (TACE) ectodomain tagged to biotin. |
Label/Conjugates | Preservative Free |
Application |
Functional Application (Blocking): Inhibits ADAM17 activity at 15μg/ml (200nM). Optimal conditions should be determined individually. |
Crossreactivity | Human |
Specificity | Recognizes the catalytic and non-catalytic domain of human ADAM17 (TACE) through its variable light (VL) domain and variable heavy (VH) domain, respectively. Does not bind recombinant mouse ADAM17 ectodomain. |
Purity | ≥95% (SDS-PAGE) |
Purity Detail | Purified by Immobilized Metal Affinity Chromatography (IMAC). |
Endotoxin Content | |
Concentration | 1mg/ml |
Formulation | Liquid. In PBS. |
Accession Number | UniProt ID P78536 |
Other Product Data | This cross-domain human antibody is a selective ADAM17 (TACE) antagonist and provides a unique alternative to small molecule metalloprotease inhibition. ADAM multidomain topology was exploited by first isolating an inhibitory human antibody (D1) that bound ADAM17-specific non-catalytic regions exclusively through its variable heavy (VH) domain. A D1-VH biased scFv phage-display library was then used to selectively isolate a new variable light (VL) chain that could simultaneously bind to the ADAM17 catalytic domain. This monovalent Fab Antibody has been shown by C.J. Tape, et al.; PNAS 108, 5578 (2011) to be as active as the divalent antibody (Prod. No. AG-27B-6000). |
Product Type | Recombinant Antibody |
追加しました。
画像
追加しました。
製品情報は掲載時点のものですが、価格表内の価格については随時最新のものに更新されます。お問い合わせいただくタイミングにより製品情報・価格などは変更されている場合があります。
表示価格に、消費税等は含まれていません。一部価格が予告なく変更される場合がありますので、あらかじめご了承下さい。